Key Event Components

  • Key Event Components (KECs) are used to describe Key Events (KEs) in a computable way, by defining an action, processes, and object term that maps to controlled vocabulary and ontology terms.
  • KECs on this page can be filtered by the action, process, and object terms, as well as by source ontologies.
  • Link to source ontology terms are provided in cases where the URL was available when the ontology terms were added to the AOP-Wiki database.
  • A complete list of all KECs is available in TSV format on the Downloads Page.
Showing 751 to 775 of 1152 KECs
Clear Table Filters
ID Action Process Object Associated Key Events (KEs)
748 decreased protein dephosphorylation (GO:0006470) signal transducer and transcription activator STAT (PR:000001933) 1716: Blockade of STAT5 phosphorylation
749 decreased cuticle development (GO:0042335) cuticle (UBERON:0001002) 1523: Decrease, Cuticular chitin content
750 decreased ecdysis, chitin-based cuticle (GO:0018990) 1524: Increase, Premature molting
751 decreased chitin synthase activity (GO:0004100) 1522: Inhibition, Chitin synthase 1
752 decreased cell proliferation (GO:0008283) cell (GO:0005623) 1821: Decrease, Cell proliferation
753 decreased growth (GO:0040007) multicellular organism (UBERON:0000468) 1521: Decrease, Growth
754 functional change gene expression (GO:0010467) Genome (FMA:84116) 1832: Coordinated gene expression changes by PPARĪ± activation
756 increased viral RNA genome replication (GO:0039694) viral RNA-directed RNA polymerase complex (GO:0031381) 1847: Increased SARS-CoV-2 production
757 increased positive stranded viral RNA replication (GO:0039690) viral RNA-directed RNA polymerase complex (GO:0031381) 1847: Increased SARS-CoV-2 production
758 increased regulation of I-kappaB kinase/NF-kappaB signaling (GO:0043122) 1172: Increased activation, Nuclear factor kappa B (NF-kB)
759 increased Venous thrombosis (HP:0004936) platelet (CL:0000233) 1846: Thrombosis and Disseminated Intravascular Coagulation
761 increased viral RNA genome packaging (GO:0019074) viral assembly compartment (GO:0072516) 1847: Increased SARS-CoV-2 production
762 increased mRNA transcription (GO:0009299) ssRNA viral genome (GO:0019024) 1847: Increased SARS-CoV-2 production
763 increased viral translation (GO:0019081) ssRNA viral genome (GO:0019024) 1847: Increased SARS-CoV-2 production
764 increased cellular response to oxidative stress (GO:0034599) reactive oxygen species (CHEBI:26523) 1869: Diminished protective oxidative stress response
766 occurrence regulation of response to reactive oxygen species (GO:1901031) reactive oxygen species (CHEBI:26523) 1634: Increase, Oxidative DNA damage
771 occurrence regulation of beta-catenin-TCF complex assembly (GO:1904863) beta-catenin-TCF complex (GO:1990907) 1755: beta-catenin activation
773 occurrence regulation of cellular response to drug (GO:2001038) 1651: Treatment-resistant gastric cancer
774 increased deoxyribonucleic acid (CHEBI:16991) 1879: Bulky DNA adducts, increase
776 decreased protein secretion (GO:0009306) vitellogenins (MESH:D014819) 285: Reduction, Vitellogenin synthesis in liver
777 decreased mRNA transcription (GO:0009299) aromatase (PR:000006100) 408: reduction in ovarian granulosa cells, Aromatase (Cyp19a1)
778 decreased protein tyrosine kinase activity (GO:0004713) tyrosine-protein kinase fyna (zebrafish) (PR:Q6EWH2) 1884: Inhibition of Fyna
779 decreased microphthalmia (MP:0001297) eye (UBERON:0000970) 1878: Decreased, Eye size
780 increased negative regulation of fibrinolysis (GO:0051918) 1866: Fibrinolysis, decreased
781 decreased negative regulation of blood coagulation (GO:0030195) 1866: Fibrinolysis, decreased